However, given the previously demonstrated requirement for activatory rather than inhibitory FcγRs in the activity of anti-CTLA-4 mAbs (Bulliard et al., 2013, Simpson et al., 2013) and the observation that anti-CTLA-4-mediated Treg cell depletion is confined to the tumor site, this was considered less relevant and the model taken forward for in vivo studies. The gene discussed is CTLA4; the disease is neoplasm.